{"result": {"id": "5c434a02-fe45-4ee4-a46a-4cc49271180d", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>复方倍他米松<|>ORGANIZATION<|>A type of glucocorticoid used for joint or muscle injections to treat inflammation, with potential side effects like hypertension and infection.\")\n##\n(\"entity\"<|>曲安奈德<|>ORGANIZATION<|>A glucocorticoid used for joint or muscle injections to reduce inflammation, with risks of adverse effects such as high blood sugar and osteoporosis.\")\n##\n(\"entity\"<|>秋水仙碱<|>ORGANIZATION<|>A medication used in small doses to prevent gout attacks during initial uric acid-lowering therapy, with alternatives like NSAIDs or prednisone if contraindicated.\")\n##\n(\"entity\"<|>非甾体抗炎药<|>ORGANIZATION<|>A class of drugs including COX-2 inhibitors and non-specific COX inhibitors, used for pain and inflammation management in conditions like gout.\")\n##\n(\"entity\"<|>泼尼松<|>ORGANIZATION<|>A glucocorticoid used in low doses for gout prevention when other medications are ineffective or contraindicated.\")\n##\n(\"entity\"<|>依托考昔<|>ORGANIZATION<|>A COX-2 specific inhibitor with a long half-life, used once daily for pain and inflammation.\")\n##\n(\"entity\"<|>艾瑞昔布<|>ORGANIZATION<|>A COX-2 specific inhibitor taken twice daily for managing inflammatory conditions.\")\n##\n(\"entity\"<|>塞来昔布<|>ORGANIZATION<|>A COX-2 specific inhibitor used twice daily for its anti-inflammatory effects.\")\n##\n(\"entity\"<|>双氯芬酸<|>ORGANIZATION<|>A non-specific COX inhibitor taken three times daily for pain and inflammation.\")\n##\n(\"entity\"<|>醋氯芬酸<|>ORGANIZATION<|>A non-specific COX inhibitor used twice daily for its anti-inflammatory properties.\")\n##\n(\"entity\"<|>布洛芬<|>ORGANIZATION<|>A non-specific COX inhibitor taken three times daily for pain relief.\")\n##\n(\"entity\"<|>吲哚美辛<|>ORGANIZATION<|>A non-specific COX inhibitor used three times daily for inflammatory conditions.\")\n##\n(\"entity\"<|>酮洛芬<|>ORGANIZATION<|>A non-specific COX inhibitor taken three times daily for pain and inflammation.\")\n##\n(\"entity\"<|>萘普生<|>ORGANIZATION<|>A non-specific COX inhibitor used three times daily for its anti-inflammatory effects.\")\n##\n(\"entity\"<|>洛索洛芬<|>ORGANIZATION<|>A COX-2 specific inhibitor taken three times daily for pain management.\")\n##\n(\"entity\"<|>美洛昔康<|>ORGANIZATION<|>A COX-2 specific inhibitor used twice daily for inflammatory conditions.\")\n##\n(\"entity\"<|>吡罗昔康<|>ORGANIZATION<|>A COX-2 specific inhibitor taken twice daily for pain and inflammation.\")\n##\n(\"relationship\"<|>复方倍他米松<|>曲安奈德<|>Both are glucocorticoids used for joint or muscle injections to treat inflammation.<|>7)\n##\n(\"relationship\"<|>秋水仙碱<|>非甾体抗炎药<|>Both are used for preventing gout attacks during uric acid-lowering therapy.<|>6)\n##\n(\"relationship\"<|>秋水仙碱<|>泼尼松<|>Both are used for gout prevention when other treatments are ineffective.<|>5)\n##\n(\"relationship\"<|>非甾体抗炎药<|>泼尼松<|>Both are alternatives for gout prevention when other medications are contraindicated.<|>5)\n##\n(\"relationship\"<|>依托考昔<|>艾瑞昔布<|>Both are COX-2 specific inhibitors used for managing inflammation.<|>7)\n##\n(\"relationship\"<|>塞来昔布<|>依托考昔<|>Both are COX-2 specific inhibitors used for anti-inflammatory effects.<|>7)\n##\n(\"relationship\"<|>双氯芬酸<|>醋氯芬酸<|>Both are non-specific COX inhibitors used for pain and inflammation.<|>7)\n##\n(\"relationship\"<|>布洛芬<|>吲哚美辛<|>Both are non-specific COX inhibitors used for inflammatory conditions.<|>7)\n##\n(\"relationship\"<|>酮洛芬<|>萘普生<|>Both are non-specific COX inhibitors used for pain and inflammation.<|>7)\n##\n(\"relationship\"<|>洛索洛芬<|>美洛昔康<|>Both are COX-2 specific inhibitors used for managing pain and inflammation.<|>7)\n##\n(\"relationship\"<|>吡罗昔康<|>美洛昔康<|>Both are COX-2 specific inhibitors used for inflammatory conditions.<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559127, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1064, "prompt_tokens": 2545, "total_tokens": 3609, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 753}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 果差，可给予关 节腔内或肌肉注射糖皮质激素，如复方倍他米松和 曲安奈德，但需排除关节感染，并避免短期内反复 注射 。应用糖皮质激素注意高血压、高血糖、高血 脂、水钠潴留、感染、胃肠道出血、骨质疏松等不良 反应。\n（四）痛风急性发作预防治疗\n　　　降尿酸治疗期间易导致反复出现急性发作症  状，可给予预防治疗 。在初始降尿酸治疗的 3~6 个  月，口服小剂量秋水仙碱 0.5 mg，1~2 次/d 。当秋水  仙碱无效或存在用药禁忌时，考虑低剂量非甾体抗  炎药作为预防性治疗 。上述两药使用存在禁忌或  疗效不佳时，亦可应用小剂量泼尼松（5~ 10 mg/d）\n\n表2    常用非甾体抗炎药的用法和用量[9]\n\n药物\t半衰期 （h）\t起效时间\n（h）\t环氧化酶选择性\t常用推荐剂量\n依托考昔\t约 22\t1\t特异性环氧化酶?2 抑制剂\t60~ 120 mg，1 次/d\n艾瑞昔布\t约 20\t2\t特异性环氧化酶?2 抑制剂\t100 mg，2 次/d\n塞来昔布\t8~ 12\t2~3\t特异性环氧化酶?2 抑制剂\t200 mg，2 次/d\n双氯芬酸\t约 2\t1/3~ 1\t非特异性环氧化酶抑制剂\t50 mg，3 次/d\n醋氯芬酸\t约 4\t1.5~3\t非特异性环氧化酶抑制剂\t100 mg，2 次/d\n布洛芬\t1.8~3.5\t1~2\t非特异性环氧化酶抑制剂\t200 mg，3 次/d\n吲哚美辛\t约 2\t1/2~2\t非特异性环氧化酶抑制剂\t50 mg，3 次/d\n酮洛芬\t1.5~2.5\t0.5~2\t非特异性环氧化酶抑制剂\t50 mg，3 次/d\n萘普生\t10~ 18\t2~4\t非特异性环氧化酶抑制剂\t250 mg，3 次/d\n洛索洛芬\t1~ 1.5\t0.5\t非特异性环氧化酶?2 抑制剂\t60 mg，3 次/d\n美洛昔康\t约 20\t4.9~6\t非特异性环氧化酶?2 抑制剂\t7.5 mg，2 次/d\n吡罗昔康\t30~60\t3~5\t非特异性环氧化酶?2 抑制剂\t10 mg，2 次/d\n\n\n\n\n·  1074   ·                                                           中华内科杂志 2023 年 9 月第 62 卷第 9 期    Chin J Intern Med, September 2023, Vol. 62, No. 9\n\n\n　预防发作，但应注意糖皮质激素长期应用的副作 用 。 目前有研究认为，采用小剂量起始、缓慢滴定 的药物降尿酸方案，明显减少痛风发作，可代替药 物预防治疗。\n（五）其他治疗\n　　　1. 慢性尿酸盐肾病：一旦确诊即开始非药物治 疗，疗效不佳者根据尿�\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_dc87c15910759d05f03fd1efa24e575c7358d5d570e6faf85316058f57325321_v2"}